Have a personal or library account? Click to login

Anaphylactic shock: are we doing enough and with the right timing and order?

Open Access
|Oct 2015

References

  1. 1. KEMP SF, LOCKEY RF. Anaphylaxis: a review of causes and mechanisms. J Allergy Clin Immunol. Sep. 2002; 110(3):341-8.
  2. 2. ALRASBI M, SHEIKH A. Comparison of international guidelines for the emergency medical management of anaphylaxis. Allergy. Aug. 2007; 62(8):838-41.
  3. 3. LAIDMAN J. Anaphylaxis requires prompt epinephrine shot. Medscape Medical News [serial online]. December 3, 2014; Accessed December 6, 2014. Available at http://www.medscape.com/viewarticle/835786.
  4. 4. CAMPBELL RL, LI JT, NICKLAS RA, SADOSTY AT. Emergency department diagnosis and treatment of anaphylaxis: a practice parameter. Ann Allergy Asthma Immunol. Dec. 2014; 113(6):599-608.
  5. 5. WORKING GROUP OF THE RESUSCITATION COUNCIL (UK). Emergency treatment of anaphylactic reactions: guidelines for healthcare providers. 2008.
  6. 6. ELLIS AK, DAY JH. Diagnosis and management of anaphylaxis. CMAJ 2003; 169:307-11.
  7. 7. AMERICAN HEART ASSOCIATION. GUIDELINES FOR CARDIOPULMONARY RESUSCITATION AND EMERGENCY CARDIOVASCULAR CARE: PART 10.6: Anaphylaxis. Circulation 2005; 112:143-5.
  8. 8. SIMONS FE. Anaphylaxis pathogenesis and treatment. Allergy. Jul. 2011; 66 Suppl 95:31-4.10.1111/j.1398-9995.2011.02629.x
  9. 9. PUMPHREY RS. Fatal posture in anaphylactic shock. J Allergy Clin Immunol. Aug. 2003; 112(2):451-2.10.1067/mai.2003.1614
  10. 10. ACUTE CARE UNDERGRADUATE TEACHING (ACUTE) INITIATIVE. A joint publication from the Resuscitation Council (UK) and Intercollegiate Board for Training in Intensive Care Medicine. 2005.
  11. 11. O’DRISCOLL BR, HOWARD LS, DAVISON AG. BTS guideline for emergency oxygen use in adult patients. Thorax 2008; 63 (Suppl 6):vi1-68.10.1136/thx.2008.102947
  12. 12. NURMATOV U, WORTH A, SHEIKH A. Anaphylaxis management plans for the acute and long-term management of anaphylaxis: a systematic review. J Allergy Clin Immunol. Aug. 2008; 122(2):353-61, 361.e1-3.
  13. 13. LIEBERMAN P. Use of epinephrine in the treatment of anaphylaxis. Curr Opin Allergy Clin Immunol. Aug. 2003; 3(4):313-8.10.1097/00130832-200308000-00013
  14. 14. KEMP SF, LOCKEY RF, SIMONS FE. Epinephrine: the drug of choice for anaphylaxis. A statement of the World Allergy Organization. Allergy. Aug. 2008; 63(8):1061-70.
  15. 15. SHEIKH A, SHEHATA YA, BROWN SGA, SIMONS FER. Adrenaline (epinephrine) for the treatment of anaphylaxis with and without shock. Cochrane Data Syst Rev 2008; 4:CD006312, doi:10.1002/14651858.CD006312.pub2
  16. 16. BRAGANZA SC, ACWORTH JP, MCKINNON DR, PEAKE JE, BROWN AF. Paediatric emergency department anaphylaxis: different patterns from adults. Arch Dis Child. Feb. 2006; 91(2):159-63.
  17. 17. YONG P. F. K., BIRNS J., IBRAHIM M. A. A. Anaphylactic shock: the great mimic. South Med. J. 2007; 100 (3): 295-297.
  18. 18. HAUSMANN O, SCHNYDER B, PICHLER WJ. Drug hypersensitivity reactions involving skin. Handb Exp Pharmacol. 2010; 196:29-5510.1007/978-3-642-00663-0_2
  19. 19. FRIEDMANN P. S., ARDERN-JONES M. Patch testing in drug Allergy. Curr. Opin. Allergy Clin. Immunol. 2010; 10 (4): 291.
  20. 20. SIMONS FE, ARDUSSO LR, BILÒ MB, EL-GAMAL YM, LEDFORD DK, RING J, et al. World Allergy Organization anaphylaxis guidelines: summary. J Allergy Clin Immunol. Mar. 2011; 127(3):587-93.e1-22.10.1016/j.jaci.2011.01.038
  21. 21. LIEBERMAN P, NICKLAS RA, OPPENHEIMER J, et al. The diagnosis and management of anaphylaxis practice parameter: 2010 update. J Allergy Clin Immunol. Sep. 2010; 126(3):477-80.e1-42.10.1016/j.jaci.2010.06.022
  22. 22. JOHANSSON SG, BIEBER T, DAHL R, FRIEDMANN PS, LANIER BQ, LOCKEY RF, et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol. May 2004; 113(5):832-6.
  23. 23. KEMP SF, LOCKEY RF. Anaphylaxis: a review of causes and mechanisms. J Allergy Clin Immunol 2002; 110:341-34810.1067/mai.2002.126811
  24. 24. AKIN C. Anaphylaxis and mast cell disease: what is the risk? Curr Allergy Asthma Rep. Jan. 2010; 10(1):34-8.
  25. 25. DYKEWICZ MS. Anaphylaxis and inflammation. Clin Allergy Immunol 2002; 16:401-409.
  26. 26. KEMP SF. Current concepts in pathophysiology, diagnosis, and management of anaphylaxis. Immunol Allergy Clin North Am 2001; 21:611-63410.1016/S0889-8561(15)30004-7
  27. 27. VADAS P, GOLD M, PERELMAN B, et al. Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis. N Engl J Med. Jan. 3 2008; 358(1):28-35.
  28. 28. NEUGUT AI, GHATAK AT, MILLER RL. Anaphylaxis in the United States: an investigation into its epidemiology. Arch Intern Med 2001; 161:15-21.10.1001/archinte.161.1.15
  29. 29. YOCUM MW, KHAN DA. Assessment of patients who have experienced anaphylaxis: a 3-year survey. Mayo Clin Proc 1994; 69:16-23.10.1016/S0025-6196(12)61606-1
  30. 30. DECKER WW, CAMPBELL RL, MANIVANNAN V, et al. The etiology and incidence of anaphylaxis in Rochester, Minnesota: a report from the Rochester Epidemiology Project. J Allergy Clin Immunol. Dec. 2008; 122(6):1161-5.
  31. 31. LIEBERMAN P. Epidemiology of anaphylaxis. Curr Opin Allergy Clin Immunol. Aug. 2008; 8(4):316-20.
  32. 32. GREENBERGER PA. Idiopathic anaphylaxis. Immunol Allergy Clin North Am. May 2007; 27 (2):273-93, vii-viii.10.1016/j.iac.2007.03.00917493503
  33. 33. WANG J, SAMPSON HA. Food anaphylaxis. Clin Exp Allergy. May 2007; 37(5):651-60.
  34. 34. HOURIHANE JO'B, KILBURN SA, NORDLEE JA, HEFLE SL, TAYLOR SL, WARNER JO. An evaluation of the sensitivity of subjects with peanut allergy to very low doses of peanut protein: a randomized, double-blind, placebo-controlled food challenge study. J Allergy Clin Immunol. Nov. 1997; 100(5):596-600.
  35. 35. BOYCE JA, ASSA'AD A, BURKS AW, JONES SM, SAMPSON HA, WOOD RA, et al. Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAID-sponsored expert panel. J Allergy Clin Immunol. Dec. 2010; 126(6 Suppl):S1-58.10.1016/j.jaci.2010.10.007424196421134576
  36. 36. GOLDEN DB, MOFFITT J, NICKLAS RA, FREEMAN T, GRAFT DF, REISMAN RE, et al. Stinging insect hypersensitivity: a practice parameter update 2011. J Allergy Clin Immunol. Apr. 2011; 127(4):852-4.e1-2310.1016/j.jaci.2011.01.02521458655
  37. 37. RUEFF F, PRZYBILLA B, BILO MB, et al. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. J Allergy Clin Immunol. Nov. 2009; 124(5):1047-54.
  38. 38. TORRES MJ, BLANCA M, FERNANDEZ J, et al, ENDA; EAACI Interest Group on Drug Hypersensitivity. Diagnosis of immediate allergic reactions to beta-lactam antibiotics. Allergy 2003; 58:961-972.10.1034/j.1398-9995.2003.00280.x14510712
  39. 39. JOHNSON K. Antibiotics common cause of perioperative anaphylaxis. Medscape Medical News [serial online]. November 22, 2013; Accessed December 3, 2013. Available at http://www.medscape.com/viewarticle/814903.
  40. 40. DAULAT S, SOLENSKY R, EARL HS, CASEY W, GRUCHALLA RS. Safety of cephalosporin administration to patients with histories of penicillin allergy. J Allergy Clin Immunol. Jun. 2004; 113(6):1220-2.
  41. 41. PICHICHERO ME. A review of evidence supporting the American Academy of Pediatrics recommendation for prescribing cephalosporin antibiotics for penicillin-allergic patients. Pediatrics. Apr. 2005; 115(4):1048-57.10.1542/peds.2004-127615805383
  42. 42. DEMOLY P, ROMANO A, BOTELHO C, et al. Determining the negative predictive value of provocation tests with beta-lactams. Allergy. 2010; 65:327-332.10.1111/j.1398-9995.2009.02228.x19860790
  43. 43. OWNBY DR. A history of latex allergy. J Allergy Clin Immunol 2002; 110:S27-S32.10.1067/mai.2002.12533612170240
  44. 44. BAUER X. Epidemiology of latex sensitization. J Allergy Clin Immunol 2003; 111:652.10.1067/mai.2003.10912642856
  45. 45. MERTES PM, MALINOVSKY JM, JOUFFROY L, et al. Reducing the risk of anaphylaxis during anesthesia: 2011 updated guidelines for clinical practice. J Investig Allergol Clin Immunol. 2011; 21(6):442-53.
  46. 46. AMIN HS, LISS GM, BERNSTEIN DI. Evaluation of near-fatal reactions to allergen immunotherapy injections. J Allergy Clin Immunol. Jan. 2006; 117(1):169-75.
  47. 47. 47.BERNSTEIN DI, WANNER M, BORISH L, LISS GM. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. J Allergy Clin Immunol. Jun. 2004; 113(6):1129-36.
  48. 48. LOCKEY RF, BENEDICT LM, TURKELTAUB PC, BUKANTZ SC. Fatalities from immunotherapy (IT) and skin testing (ST). J Allergy Clin Immunol. Apr. 1987; 79(4):660-77.
  49. 49. LEE S, HESS EP, NESTLER DM, BELLAMKONDA ATHMARAM VR, BELLOLIO MF, DECKER WW, et al. Antihypertensive medication use is associated with increased organ system involvement and hospitalization in emergency department patients with anaphylaxis. J Allergy Clin Immunol. Apr. 2013; 131(4):1103-8.
  50. 50. BOGGS W. Anaphylaxis worse with antihypertensive medication. Medscape Medical News. March 21, 2013. Available at http://www.medscape.com/viewarticle/781274.
  51. 51. KATAYAMA H, YAMAGUCHI K, KOZUKA T, TAKASHIMA T, SEEZ P, MATSUURA K. Adverse reactions to ionic and nonionic contrast media. A report from the Japanese Committee on the Safety of Contrast Media.Radiology. Jun. 1990; 175(3):621-8.
  52. 52. GREENBERGER PA, PATTERSON R. The prevention of immediate generalized reactions to radiocontrast media in high-risk patients. J Allergy Clin Immunol. Apr. 1991; 87(4):867-72.
  53. 53. SLATER JE, RAPHAEL G, CUTLER GB JR, LORIAUX DL, MEGGS WJ, KALINER M. Recurrent anaphylaxis in menstruating women: treatment with a luteinizing hormone-releasing hormone agonist – a preliminary report. Obstet Gynecol. Oct. 1987; 70(4):542-6.
  54. 54. KEMP SF. The post-anaphylaxis dilemma: how long is long enough to observe a patient after resolution of symptoms? Curr Allergy Asthma Rep. Mar. 2008; 8(1):45-8.
  55. 55. POSADAS SJ, PICHLER WJ. Delayed drug hypersensitivity reactions – new concepts. Clin Exp Allergy. 2007; 37:989-999.10.1111/j.1365-2222.2007.02742.x17581192
  56. 56. LIEBERMAN PL. Specific and idiopathic anaphylaxis: pathophysiology and treatment. In: Bierman CW, Pearlman DS, Shapiro GG, et al., eds. Allergy, Asthma and Immunology From Infancy to Adulthood. Third edition. Philadelphia, WB Saunders, 1996, pp. 297-319.
  57. 57. SIMONS FE, SAMPSON HA. Anaphylaxis epidemic: fact or fiction? J Allergy Clin Immunol. Dec. 2008; 122(6):1166-8.
  58. 58. MONERET-VAUTRIN DA, MORISSET M, FLABBEE J, BEAUDOUIN E, KANNY G. Epidemiology of life-threatening and lethal anaphylaxis: a review. Allergy. Apr. 2005; 60(4):443-51.
  59. 59. DEMUTH KA, FITZPATRICK AM. Epinephrine autoinjector availability among children with food allergy. Allergy Asthma Proc. Jul. 2011; 32(4):295-300.
  60. 60. JOSE R, CLESHAM GJ. Survey of the use of epinephrine (adrenaline) for anaphylaxis by junior hospital doctors. Postgrad Med J 2007; 83:610-1.10.1136/pgmj.2007.059097260000917823230
DOI: https://doi.org/10.1515/rjim-2015-0026 | Journal eISSN: 2501-062X | Journal ISSN: 1220-4749
Language: English
Page range: 191 - 198
Submitted on: Jan 15, 2015
Published on: Oct 14, 2015
Published by: N.G. Lupu Internal Medicine Foundation
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year

© 2015 H. Bălan, Adriana Gurghean, published by N.G. Lupu Internal Medicine Foundation
This work is licensed under the Creative Commons Attribution 4.0 License.